Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis

Journal of Infection and Chemotherapy

Volumn 10, Issue 5, 2004, Pages 262-267

  Yokoi, Shigeaki ^a   Yasuda, Mitsuru ^a   Ito, Shin Ichi ^a   Takahashi, Yoshihito ^a   Ishihara, Satoshi ^a   Deguchi, Takashi ^a   Maeda, Shin Ichi ^b   Kubota, Yasuaki ^b   Tamaki, Masayoshi ^b   Fukushi, Hideto ^a  

^a GIFU UNIVERSITY   (Japan)

^b TOYOTA MEMORIAL HOSPITAL   (Japan)

Author keywords

Chlamydia trachomatis; Fluoroquinolone resistance; GyrA; ParC

Indexed keywords

AMINO ACID; ARGININE; CYSTEINE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ERYTHROMYCIN; GLYCINE; LEVOFLOXACIN; MINOCYCLINE; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TETRACYCLINE; TOSUFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; GENE AMPLIFICATION; HELA CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; URETHRITIS; URINE;

EID: 19944428034     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0332-4     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases 2002. Morb Mortal Wkly Rep 2002;51 (RR06):1-80.
2. Joly-Guillou ML, Lasry S. Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis epididymitis and prostatitis. Drugs 1999;57: 743-50.
3. Japanese Society for Sexually Transmitted Diseases. Guidelines for the diagnosis and treatment of sexually transmitted diseases. Jpn J Sex Transm Dis 1999;10:7-38.
4. Lefevre JC, Lepargneur JP, Guion D, Bei S. Tetracycline-resistant Chlamydia trachomatis in Toulouse France. Pathol Biol (Paris) 1997;45:376-8.
5. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000;181:1421-7.
6. Dessus-Babus S. Bebear CM, Charron A, Bebear C, de Barbeyrac B. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998;42:2474-81.
7. Morrissey I, Salman H, Bakker S, Farrell D, Bebear CM, Ridgway G. Serial passage of Chlamydia spp. In sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother 2002;49:757-61.
8. Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990;34:1271-2.
9. Nakamura S. Mechanisms of quinolone resistance. J Infect Chemother 1997;3:128-38.
10. Katoh N, Itoh Y, Deguchi T, Kanematsu M, Ban Y, Kawada Y, et al. Isolation of Chlamydia trachomatis from patients with urethritis. Kansenshogaku Zasshi 1984;58:29-38.
11. Japanese Society of Chemotherapy. Method for in vitro determination of chlamydial susceptibility (minimum inhibitory concentration; MIC) to antimicrobial agents - standard method of Japan Society of Chemotherapy. Chemotherapy (Tokyo) 1992;40: 308-14.
12. Yoshida T, Maeda S, Deguchi T, Ishiko H. Phylogeny-based rapid identification of mycoplasmas and ureaplasmas from urethritis patients. J Clin Microbiol 2002;40:105-10.
13. Deguchi T, Yasuda M, Asano M, Tada K, Iwata H, Komeda H, et al. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1995;39: 561-3.
14. Maeda S-I, Tamaki M, Kojima K, Yoshida T, Ishiko H, Yasuda M, et al. Association of Mycoplasma genitalium persistence in the urethra with recurrence of nongonococcal urethritis. Sex Transm Dis 2001;28:472-6.
15. Deguchi T, Maeda S-I, Tamaki M, Yoshida T, Ishiko H, Ito M, et al. Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother 2001;48:742-4.
16. Huang WM. Bacterial diversity based on type II DNA topoisomerase genes. Annu Rev Genet 1996;30:79-107.
17. Nagayama A, Nakao T, Taen H. In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis. Antimicrob Agents Chemother 1988;32:1735-7.
18. Ridgway GL. Quinolones in sexually transmitted diseases: state of the art. Drugs 1999;58 (Suppl 2):92-5.
19. Yasuda M, Fukuda H, Yokoi S, Ishihara S, Kawada Y, Deguchi T. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV. J Urol 2000;164:847-51.
20. Mardh PA, Persson K. Is there a need for rescreening of patients treated for genital chlamydial infections? Int J STD AIDS 2002; 13:363-7.
21. Blomer R, Bruch K, Klose U. Ofloxacin in the treatment of gonococcal and chlamydial urethritis. Clin Ther 1988;10:263-5.
22. Hooton TM. Batteiger BE, Judson FN, Spruance SL, Stamm WE. Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis. Antimicrob Agents Chemother 1992; 36:1144-6.
23. Kitchen VS, Donegan C, Ward H, Thomas B, Harris JR, Taylor-Robinson D. Comparison of ofloxacin with doxycycline in the treatment of non-gonococcal urethritis and cervical chlamydial infection. J Antimicrob Chemother 1990;26 (Suppl D):99-105.
24. Takahashi S, Hagiwara T, Shiga S, Hirose T, Tsukamoto T. In vitro analysis of the change in resistance of Chlamydia trachomatis under exposure to sub-MIC levofloxacin for a therapeutic term. Chemotherapy 2000;46:402-7.
25. Nakata K, Maeda H, Fujii A, Arakawa S, Umezu K, Kamidono S. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis. Antimicrob Agents Chemother 1992;36:188-90.
26. Donati M, Rodriguez Fermepin M, Olmo A, D'Apote L, Cevenini R. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J Antimicrob Chemother 1999;43:825-7.